Conventional cytogenetics in myelofibrosis: Literature review and discussion

European Journal of Haematology

Volumn 82, Issue 5, 2009, Pages 329-338

  Hussein, Kebede ^a   Van Dyke, Daniel L ^b   Tefferi, Ayalew ^a,b  

^a Division of Hematology   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Cytogenetic; Karyotype; Polycythemia; Prognosis; Thrombocythemia

Indexed keywords

JANUS KINASE 2;

CHROMOSOME DELETION; CHROMOSOME DELETION 12; CHROMOSOME DELETION 13; CHROMOSOME DELETION 20; CHROMOSOME DELETION 5; CHROMOSOME DELETION 7; CHROMOSOME DUPLICATION; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 6; CYTOGENETICS; DIAGNOSTIC VALUE; GENE MUTATION; HUMAN; MYELOFIBROSIS; PARTIAL TRISOMY 9; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL; THROMBOCYTHEMIA; TREATMENT PLANNING; TRISOMY 8;

CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DIAGNOSIS, DIFFERENTIAL; HUMANS; PRIMARY MYELOFIBROSIS; PROGNOSIS; SEQUENCE DELETION;

EID: 64249164411     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01224.x     Document Type: Review

References (49)

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008 22 : 14 22.
2. Tefferi A, Gangat N, Wolanskyj AP, Schwager S, Pardanani A, Lasho TL, Mesa R, McClure RF, Li CY, Hanson CA. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Eur J Haematol 2008 80 : 386 90.
3. Cervantes F, Dupriez B, Pereira A, et al. A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for myelofibrosis research and treatment. Blood doi :. 10.1182/blood-2008-07- 170449
4. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 2008 83 : 491 7.
5. Vardiman JW, Brunning RD, Arber DA, Le Beau MM, Porwit A, Tefferi A, Bloomfield CD, Thiele J. Introduction and overview of the classification of the myeloid neoplasms. In : Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, ed. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Vol. 4th Edition. Lyon : International Agency for Research on Cancer, 2008 : 18 30.
6. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008 22 : 1299 307.
7. Reilly JT. Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs). Leukemia 2008 22 : 1818 27.
8. Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, Kettering RP, Hanson CA, Van Dyke DL, Tefferi A. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol 2009 in press.
9. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001 113 : 763 71.
10. Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A, Potter A. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997 98 : 96 102.
11. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996 88 : 1013 8.
12. Tefferi A, Dingli D, Li CY, Dewald GW. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer 2005 104 : 1656 60.
13. Reilly JT, Wilson G, Barnett D, Watmore A, Potter A. Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis. Br J Haematol 1994 88 : 575 81.
14. Djordjevic V, Dencic-Fekete M, Jovanovic J, Bizic S, Jankovic G, Bogdanovic A, Cemerikic-Martinovic V, Gotic M. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients. Cancer Genet Cytogenet 2007 173 : 57 62.
15. Demory JL, Dupriez B, Fenaux P, Lai JL, Beuscart R, Jouet JP, Deminatti M, Bauters F. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood 1988 72 : 855 9.
16. Andrieux J, Demory JL, Caulier MT, Agape P, Wetterwald M, Bauters F, Lai JL. Karyotypic abnormalities in myelofibrosis following polycythemia vera. Cancer Genet Cytogenet 2003 140 : 118 23.
17. Miller JB, Testa JR, Lindgren V, Rowley JD. The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis. Cancer 1985 55 : 582 91.
18. Strasser-Weippl K, Steurer M, Kees M, et al. Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia. Cancer 2006 107 : 2801 6.
19. Strasser-Weippl K, Steurer M, Kees M, Augustin F, Tzankov A, Dirnhofer S, Fiegl M, Gisslinger H, Zojer N, Ludwig H. Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia. Blood 2005 105 : 4146.
20. Smadja N, Krulik M, de Gramont A, Sirinelli A, Brissaud P, Dray C, Audebert AA, Debray J. Cytogenetic studies in twelve patients with primary myelofibrosis and myeloid metaplasia. Cancer Genet Cytogenet 1987 24 : 151 8.
21. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for myelofibrosis research and treatment. Leukemia 2008 22 : 437 8.
22. Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer 2006 106 : 1985 9.
23. Gangat N, Strand J, Lasho TL, Finke CM, Knudson RA, Pardanani A, Li CY, Ketterling RP, Tefferi A. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol 2008 80 : 197 200.
24. Swolin B, Weinfeld A, Westin J. A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 1988 72 : 386 95.
25. Westin J, Wahlstrom J, Swolin B. Chromosome studies in untreated polycythaemia vera. Scand J Haematol 1976 17 : 183 96.
26. Swolin B, Weinfeld A, Westin J. Trisomy 1q in polycythemia vera and its relation to disease transition. Am J Hematol 1986 22 : 155 67.
27. Wolanskyj AP, Gangat N, Schwager SM, Ketterling RP, Tefferi A. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. ASH Annual Meeting Abstracts 2006 108 : 3626.
28. Dingli D, Grand FH, Mahaffey V, Spurbeck J, Ross FM, Watmore AE, Reilly JT, Cross NC, Dewald GW, Tefferi A. Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia. Br J Haematol 2005 130 : 229 32.
29. Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol 2002 108 : 55 65.
30. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005 105 : 973 7.
31. Swolin B, Rodjer S, Westin J. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature. Ann Hematol 2008 87 : 467 74.
32. Passamonti F, Rumi E, Arcaini L, et al. Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer 2005 104 : 1032 6.
33. Sessarego M, Defferrari R, Dejana AM, Rebuttato AM, Fugazza G, Salvidio E, Ajmar F. Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study. Cancer Genet Cytogenet 1989 43 : 57 65.
34. La Starza R, Wlodarska I, Aventin A, Falzetti D, Crescenzi B, Martelli MF, Van den Berghe H, Mecucci C. Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies. Blood 1998 91 : 231 7.
35. Bench AJ, Nacheva EP, Hood TL, et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 2000 19 : 3902 13.
36. Douet-Guilbert N, Basinko A, Morel F, Le Bris MJ, Ugo V, Morice P, Berthou C, De Braekeleer M. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions. Ann Hematol 2008 87 : 537 44.
37. Howard-Reeves J, Valganon M, Mazzullo H, Grace C, Campbell L, Nacheva E. Unbalanced chromosome rearrangements involving the 20q11.2 region in myeloid malignancy. ASH Annual Meeting Abstracts 2008 112 : 2055.
38. Santana-Davila R, Tefferi A, Holtan SG, Ketterling RP, Dewald GW, Knudson RA, Steensma DP, Chen D, Hoyer JD, Hanson CA. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases. Leuk Res 2008 32 : 1927 30.
39. Holtan SG, Santana-Davila R, Dewald GW, et al. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era. Am J Hematol 2008 83 : 708 13.
40. Santana-Davila R, Holtan SG, Dewald GW, Ketterling RP, Knudson RA, Hanson CA, Steensma DP, Tefferi A. Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution. Leuk Res 2008 32 : 407 11.
41. Lehmann S, O'Kelly J, Raynaud S, Funk SE, Sage EH, Koeffler HP. Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia 2007 21 : 1931 6.
42. Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007 104 : 11406 11.
43. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008 451 : 335 9.
44. Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 2007 21 : 1827 8.
45. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006 355 : 1456 65.
46. Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W. Single agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood 2009 113 : 1002 1005.
47. Mesa R, Hanson CA, Kettering RP, Schwager S, Knudson RA, Tefferi A. Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality. Blood 2009 113 : 1200 1201.
48. Najfeld V, Montella L, Scalise A, Fruchtman S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol 2002 119 : 558 66.
49. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007 110 : 4385 95.